SCHEMBL16469412

SCHEMBL16469412

COC(=O)c1ccc(NS(=O)(=O)c2ccc(C=O)cc2C)cc1F

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SIRT6 Q8N6T7 1/20 0.46
ALDH1A1 P00352 4/20 0.43
HSD17B10 Q99714 1/20 0.42
MAPT P10636 5/20 0.42
FABP4 P15090 2/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
TP53 P04637 2/20 0.39
FABP5 Q01469 1/20 0.39
IDH1 O75874 1/20 0.39
LMNA P02545 3/20 0.38
HPGD P15428 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
PKM P14618 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
CDK1 P06493 1/20 0.38
CMA1 P23946 1/20 0.37
THRB P10828 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18009516 0.84 SIRT6 (0.52) SIRT6ALDH1A1HSD17B10MAPTFABP4
SCHEMBL16469334 0.83 ALDH1A1 (0.49) SIRT6ALDH1A1HSD17B10FABP4FABP5
SCHEMBL16469809 0.82 SIRT6 (0.46) SIRT6ALDH1A1HSD17B10MAPTFABP4
SCHEMBL18027982 0.82 SIRT6 (0.46) SIRT6ALDH1A1HSD17B10MAPTFABP4
SCHEMBL28624757 0.81 SIRT6 (0.46) SIRT6ALDH1A1HSD17B10MAPTFABP4
SCHEMBL16469956 0.79 SIRT6 (0.43) SIRT6ALDH1A1HSD17B10MAPTFABP4
SCHEMBL28127771 0.79 SIRT6 (0.44) SIRT6ALDH1A1HSD17B10MAPTFABP4
SCHEMBL18009513 0.78 SIRT6 (0.42) SIRT6ALDH1A1HSD17B10MAPTFABP4
SCHEMBL1498919 0.78 ALDH1A1 (0.53) ALDH1A1HSD17B10MAPTHPGDSMN1; SMN2
SCHEMBL18009535 0.77 KAT6A (0.43) SIRT6ALDH1A1MAPTFABP4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9533985-B2 Sulfonamide derivative and medicinal use thereof EA PHARMA CO., LTD. (JP) 2017-01-03 US disclosed
US-9533985-B2 Sulfonamide derivative and medicinal use thereof EA PHARMA CO., LTD. (JP) 2017-01-03 US disclosed
US-20150051395-A1 SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF AJINOMOTO CO., LTD. (JP) 2015-02-19 US disclosed
US-20150051395-A1 SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF AJINOMOTO CO., LTD. (JP) 2015-02-19 US disclosed
US-20150051395-A1 SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF AJINOMOTO CO., LTD. (JP) 2015-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051395-A1 SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF ITGB4, ITGA4, ITGA2 SIRT6 2659/4885ALDH1A1 1151/4885HSD17B10 4530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.